Benzinga · Aug 26, 2026
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
AB
NYSE · ABT
Abbott Laboratories
Healthcare · Medical - Devices
$112.47
Up+$0.88 (+0.79%)
Updated Aug 31, 2026, 8:24 AM
SID Score
7.3/10
Composite research score
Smart Money
50/100
Neutral
- Market cap
- 202.45B
- P/E ratio
- 31.15
- Dividend yield
- 2.10%
- 52-week range
- $81.97 – $129.64
- Volume
- 7.55M
- Avg. volume
- 8.88M
Price performance
ABT price history
1M range · 20 trading sessions · Daily adjusted prices
ABT closed at $112.47 after 20 trading sessions, up 4.99% for the selected period.
- Last close
- $112.47
- Period change
- +4.99%
- Period low
- $105.46
- Period high
- $116.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $111.60 | $112.75 | $111.11 | $112.47 | 7.55M |
| Aug 27, 2026 | $112.75 | $113.45 | $111.29 | $111.59 | 8.36M |
| Aug 26, 2026 | $115.40 | $116.715 | $114.005 | $114.10 | 6.96M |
| Aug 25, 2026 | $115.83 | $116.61 | $115.035 | $116.13 | 7.5M |
| Aug 24, 2026 | $116.28 | $117.34 | $115.82 | $116.67 | 5.92M |
| Aug 21, 2026 | $114.02 | $116.66 | $113.4501 | $116.64 | 9.93M |
| Aug 20, 2026 | $114.00 | $115.23 | $113.99 | $114.14 | 5.79M |
| Aug 19, 2026 | $113.23 | $115.67 | $112.91 | $114.43 | 7.4M |
| Aug 18, 2026 | $112.45 | $113.63 | $111.745 | $112.68 | 9.78M |
| Aug 17, 2026 | $110.04 | $111.41 | $109.35 | $110.37 | 11.46M |
| Aug 14, 2026 | $111.49 | $111.97 | $110.79 | $111.25 | 5.58M |
| Aug 13, 2026 | $112.47 | $112.47 | $110.46 | $111.27 | 5.52M |
| Aug 12, 2026 | $108.05 | $111.28 | $107.50 | $110.91 | 6.61M |
| Aug 11, 2026 | $108.62 | $110.185 | $107.921 | $109.72 | 6.74M |
| Aug 10, 2026 | $107.41 | $109.09 | $107.36 | $108.62 | 5.6M |
| Aug 7, 2026 | $107.03 | $107.97 | $106.01 | $107.81 | 6.61M |
| Aug 6, 2026 | $107.185 | $107.99 | $105.56 | $107.96 | 9.8M |
| Aug 5, 2026 | $106.71 | $106.76 | $104.20 | $105.71 | 9.31M |
| Aug 4, 2026 | $105.77 | $106.19 | $104.92 | $105.46 | 8.16M |
| Aug 3, 2026 | $107.85 | $109.33 | $106.43 | $107.12 | 7.41M |
Latest ABT news
The latest Smart Investors Daily articles mentioning ABT.
Stock researchCompany · Overview
ABT research
Overview
Company profile and research snapshot.
Company profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $151.40
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 17, 2026 | TD Cowen | Buy | — |
| Jul 17, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 26, 2026
Abbott Laboratories (NYSE:ABT) Clears All Quality Investing Hurdles
Discover why Abbott Labs (ABT) clears a quality screen with high ROIC, solid growth, and 96.8% profit quality. Valuation below market adds appeal.
Benzinga · Aug 25, 2026
FDA Authorizes Abbott's Libre Duo, First Device To Continuously Monitor Both Glucose And Ketones
The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes. The Libre Duo 10 Day is the first
Benzinga · Aug 25, 2026
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
AI research layers
Interpretive context generated from the platform’s current data sources.
Abbott Laboratories Stock Performance
Abbott Laboratories shares traded at $112.47, reflecting a modest daily gain of 0.47% per SID market data. The stock has demonstrated significant short-term momentum, rising 6.5% over the past month and surging 31.39% over the trailing three-month period. However, on a one-year basis, ABT remains down 10.23%, indicating that the recent rally represents a recovery from prior weakness rather than a breakout to new highs. Technically, the stock trades above both its 50-day moving average of $102.45 and its 200-day moving average of $103.98, according to SID market data, signaling a bullish trend structure. The 14-day RSI reads 61.7, placing it in neutral-to-moderately-bullish territory without reaching overbought levels. ABT carries a beta of 0.751, confirming its defensive characteristics relative to the broader market. Average daily trading volume stands at approximately 8.88 million shares, supporting adequate liquidity for institutional positioning.
Abbott Laboratories Valuation Analysis
Abbott Laboratories carries a market capitalization of approximately $202.5 billion and trades at a price-to-earnings ratio of 31.15, according to SID market data. This valuation sits at a premium relative to the broader healthcare sector, reflecting the market's pricing of Abbott's diversified medical device and diagnostics portfolio. The price-to-book ratio stands at 3.90, per SEC filings, indicating moderate asset-based valuation. Notably, the PEG ratio registers at negative 0.58, a figure that warrants attention as it suggests either a temporary earnings contraction or a transitional growth period in analyst models. Abbott maintains a dividend yield of 2.06%, which aligns with its status as a Dividend Aristocrat with decades of consecutive payout increases. The current valuation metrics reflect a stock that has re-rated higher during its three-month 31.39% rally, compressing the yield and expanding the earnings multiple from levels seen earlier in the trailing twelve-month period.
Smart Money Activity for ABT
Abbott Laboratories registers a smart money composite score of 50 out of 100, reflecting a neutral overall signal per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained buying from large asset managers and pension funds — a strong vote of confidence in Abbott's long-term fundamentals. In contrast, the insider trading score sits at 9.7 out of 25, with SEC Form 4 filings revealing 14 insider transactions over the past 90 days, evenly split between 7 purchases and 7 sales. This balanced insider activity suggests neither conviction buying nor aggressive liquidation among corporate officers and directors. The dark pool activity score registers at 8.5 out of 25, pointing to below-average institutional block trading activity through alternative venues. Congressional trading scored 6.4 out of 25, per 13F institutional filings and disclosure records, indicating minimal notable positioning by lawmakers. The institutional strength remains the dominant positive factor within the smart money framework.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has delivered consistent earnings results, meeting or exceeding analyst expectations in its most recent reported quarters. In the latest reported quarter, the company posted earnings per share of $1.31 against a consensus estimate of $1.28, representing a positive surprise of $0.03, according to company earnings reports. The prior quarter showed EPS of $1.15 versus an estimate of $1.14, a $0.01 beat. In the January 2026 reporting period, Abbott matched consensus precisely at $1.50 per share with zero surprise. An upcoming report is scheduled for April 15, 2026, with analysts projecting EPS of $1.15 per analyst estimates. The pattern of narrow beats demonstrates Abbott's earnings predictability while also highlighting limited upside surprise magnitude. The sequential progression from $1.50 to $1.15 to $1.31 reflects the typical seasonality inherent in Abbott's medical devices and diagnostics segments, where fourth-quarter results historically outpace mid-year periods.
Wall Street Analyst Ratings for ABT
Wall Street consensus on Abbott Laboratories remains decisively positive, with recent analyst actions uniformly reflecting bullish positioning. On August 25, 2026, TD Cowen maintained its Buy rating on ABT, following a similar reiteration by UBS on July 28, per Wall Street analyst reports. RBC Capital maintained its Outperform rating on July 17, reinforcing the constructive institutional view. The most notable upgrade came from Wolfe Research on August 13, which elevated ABT from Peer Perform to Outperform, signaling a meaningful shift in conviction from a previously neutral stance. According to SID consensus data, no recent downgrades or Sell ratings have been issued among tracked analysts. The clustering of positive reiterations following Abbott's earnings beat of $1.31 versus the $1.28 estimate suggests that the results validated existing bullish theses. TD Cowen issued two separate notes in the period — a post-earnings reiteration and a subsequent sector-level maintenance — both sustaining the Buy recommendation.
